Search

News Webinar SGLT2i in ESC HF Guidelines vs. Real Practice

Dear Doctor, Boehringer Ingelheim, in collaboration with the 2nd Department of Internal Medicine -⁠ Department of Cardiology and Angiology, General University Hospital and 1st Faculty of Medicine, Charles University, cordially invites you to an online discussion to be held on Tuesday, November 23, 2021, from 5 : 00 PM to 6 : 30 PM. More information can be found in the attached invitation below.

Source: Heart Failure 18. 11. 2021

News Quality of Life in Patients with mCRC Treated with mFOLFOXIRI and Panitumumab

At the congress of the European Society for Medical Oncology (ESMO) in September 2019, the results of the VOLFI study were presented, which also monitored the quality of life in patients with primarily unresectable wild-type (wt-RAS) metastatic colorectal cancer (mCRC) with an ECOG performance status of 0–1.

Source: Colorectal Cancer 16. 6. 2020

News Documented Cardiovascular Benefit of Empagliflozin in New American Diabetes Treatment Guidelines

Two leading overseas medical professional societies, the American Diabetes Association (ADA) and the American Association of Clinical Endocrinologists (AACE), released new recommendations for diabetes treatment in December 2016. They include information on the reduction of cardiovascular mortality in diabetics treated with empagliflozin (Jardiance).

Source: Diabetes 14. 2. 2020

News Current Status in the Issue of Alpha-1-Antitrypsin Deficiency

Material by Italian and Swiss authors published in the European Respiratory Review details current insights into alpha-1-antitrypsin (AAT) deficiency and the possibilities for its diagnosis and treatment. We provide a summary of the main points, including the specific option of augmentation therapy with exogenous AAT.

Source: Deficiency of Alpha-1-Antitrypsin 12. 1. 2022

News Association Between Sartan Therapy and Lower Incidence of Epilepsy in Hypertensive Patients?

Arterial hypertension (AH) is one of the non-cerebral comorbidities of epilepsy, with the renin-angiotensin system possibly being the central mediator of the connection between these diseases. The German study cited below therefore examined whether therapy with AT1 receptor blockers for angiotensin II (ARBs, i.e., sartans) reduces the risk of epilepsy in patients with AH as suggested by animal studies.

Source: Sartans in the Treatment of Hypertension 25. 5. 2023

News Recent Advances in Physiotherapy for Hemophiliacs

Physiotherapy specifically focuses on movement and the movement potential of the individual, with the purpose of restoring or maintaining maximum mobility and functional abilities throughout life. Numerous experiences have shown that physiotherapeutic procedures hold a key position for patients with hemophilia.

Source: Hemophilia with Movement 28. 1. 2021

News Transition of Hemophilia A Patients with a History of Coagulation Factor Inhibitor to Emicizumab

During the World Federation of Hemophilia (WFH) conference, held virtually in June 2020, interesting results were presented for patients with Hemophilia A who had a history of FVIII inhibitor and are now using Emicizumab.

Source: Quality Life Even with Hemophilia 3. 8. 2020

News The Role of Probiotics in the Prevention of Childhood Infections

Although common acute respiratory and gastrointestinal infections are a part of childhood, they pose a significant burden on families and the healthcare and social care system. An unexpected role in their prevention can be played by the gut microbiome, specifically its support through certain probiotics. However, it is necessary to choose products supported by clinical studies.

Source: GI, colic and microbiome 11. 2. 2020

News Brentuximab Vedotin as Another Therapeutic Option in Cutaneous T-Cell Lymphoma

Current systemic treatment for patients with cutaneous T-cell lymphoma (CTCL) unfortunately has limited efficacy, achieving low response rates and short-lasting remissions. Moreover, there is no curative therapy modality for advanced stages of CTCL. However, the results of the recently concluded ALCANZA clinical trial indicate the potential of brentuximab vedotin in this indication.

Source: Hematologic Malignancies 4. 1. 2022

News Use of Enoxaparin in Patients After Implantation of Left Ventricular Assist Device

Left ventricular assist devices (LVAD) are utilized in patients with end-stage heart failure (HF). Warfarin is typically employed for long-term anticoagulation, but there are no standardized recommendations for anticoagulant therapy during the postoperative period. One option to bridge the time until therapeutic INR is achieved after LVAD implantation is the low molecular weight heparin (LMWH) enoxaparin, which was investigated for its efficacy and safety in this indication by experts from Kansas, USA, cited in the following study.

Source: Thromboprophylaxis 28. 11. 2023

News New Solution for Moderate Incontinence –⁠ Discreet Pull-Up Diaper Pants

The range of products for people with incontinence is constantly expanding –⁠ recent additions include pull-up diaper pants labeled Seni Active Basic and Seni Active Classic.

Source: Incontinence 30. 8. 2022

News Romiplostim in a Pregnant Woman −⁠ Case Report

The following clinical case demonstrates good control of resistant immune thrombocytopenia in a pregnant woman during the administration of romiplostim.

Source: Immune Thrombocytopenia 16. 5. 2022

News Effect of Administering Ferric Carboxymaltose on Quality of Life in Heart Failure Patients

The quality of life in patients with heart failure is significantly reduced. The concurrent occurrence of iron deficiency further exacerbates this situation. The AFFIRM-AHF study evaluated the impact of intravenous administration of ferric carboxymaltose on health-related quality of life (HRQoL) in patients with heart failure who also suffered from iron deficiency.

Source: Iron Deficiency and Anemia 7. 2. 2022

News Options for Tapering TPO-RA in ITP Patients: Practical Experience and Expert Consensus

A recently published British study aims to provide recommendations on tapering TPO-RA in patients with immune thrombocytopenia (ITP) based on existing evidence, survey results of clinical practice among hematologists, and expert consensus.

Source: Immune Thrombocytopenia 25. 10. 2022

News EMPATHY Questionnaire as a Tool for Better Personalization of Levothyroxine Doses in Patients with Primary Hypothyroidism?

The therapy for hypothyroidism consists of substitution with levothyroxine (L-T4). Failure to achieve the target thyrotropin hormone (TSH) level can be due to non-compliance (in 60% of cases) or malabsorption of the drug (in 40%). The aim of the presented Italian study was the validation of the EMPATHY questionnaire for better personalization of therapy.

Source: Thyroid Disorders 25. 10. 2022